METCrusaders

Amy, we are so happy to have you as one of our beloved patient leaders at @metcrusaders

Must-read on MET alterations: jto.org/action/showPdf…

Our paper is online @JTOonline Molecular Profiling across 80,000 Patients with Lung Cancer. A robust demonstration that we need to test all patients with NSCLC & ALL histologies and open the door for nomenclature change. jto.org/article/S1556-… @Al3ssandroRusso @OhioStateMedOnc

#NORTHSTAR update #ELCC26 1️⃣Post-osi CT @ 6-12 wks •Nodes cleared: 41.5 v 19.6 mo •Persistent: no benefit •Effusion gone: 32.7 v 22.3 mo •Persistent: no benefit 2️⃣RT w/ strong local control •8% in v 92% out-of-field 3️⃣RT technique •BED≥75:⬆️outcomes •V20<25%:⬇️toxicity

In 2019, MIT professor Patrick Winston gave a legendary 1-hour lecture called “How to Speak.” It has 18M+ views for a reason. His frameworks: • Your ideas are like your children • The 5-minute rule for job talks • Why jokes fail at the start 15 lessons on communication:

Technion researchers Dr. Gil Shamai, Prof. Ron Kimmel (Computer Science), and Prof. Dvir Aran (Biology) have developed an AI model that predicts who will benefit from chemotherapy—using routine pathology images, in minutes. A step toward faster, more accessible personalized cancer care. #Technion #AIinHealthcare #BreastCancer #PrecisionMedicine technion.ac.il/en/blog/articl… thelancet.com/journals/lanon…

I am honored and excited to announce that I will join the Dartmouth community in July as Director of the Dartmouth Cancer Center. Looking forward to continuing the important work of advancing cancer care, research, and patient impact. @DartmouthCancer @GeiselMed geiselmed.dartmouth.edu/news/2026/dart…

Longer follow up from LUMINOSITY study @JTOonline: telisotuzumab vedotin (cMET ADC) in cMET+, EGFR wild type, non-squamous NSCLC had RR 29.2% with DOR 7.2m. In cMET high, RR 34.5% and in cMET int, RR 23.8%. Neuropathy seen in 31% (7% G3+). jtocrr.org/article/S2666-…

🫁 Catching up on NORTHSTAR trial data before #ELCC26? ⭐ Don't miss this insightful interview with @maraantonoff, who unpacks the surgical outcome data that she presented at #STS2026! ➡️ Watch now: buff.ly/NrYZA6D #lcsm #NSCLC #EGFR

Congratulations to first author @NiamhColeman @stjamesdublin and all co-authors on publication of the results of NCI-MATCH Arms C1/C2. "Crizotinib demonstrated clinical activity across tumors with METamp and METex14." #PrecisionOncology @theNCI #CancerResearch

@RaviJainMD @diegoadiazg @dr_yakupergun @DrJNaidoo @Latinamd @lungoncdoc @AndresFCardonaZ Some guiding principles: 1) Irrespective of PDL1, I avoid ICIs in pts w/ certain AGAs (EGFR, ALK, ROS1, RET, NTRK, HER2ex20). Data mixed for KRAS or METEx14, but favor TKI in latter. 2) I consider CTLA4 for KEAP1, but clinical data is VERY mixed 3) Smoking history is huge.

🔜 #ELCC26 @myESMO 🇩🇰 🔥Don’t miss the target: BRAF, HER2, METex14 and EGFR exon20 in focus ☑️ #BRAF #HER2 #METex14 #EGFRex20ins 🎙️Chair: Dr. Caicun Zhou, Dr. Natasha Leighl @OncoAlert @Larvol #LCSM

Revolutionize your NSCLC diagnostics with Idylla™ 🏆 Test for EGFR, ALK, ROS1, RET & METex14 in ONLY 3 HOURS and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers*. 👉🏻biocartis.com/sites/default/… *biocartis.com/en/reference-h…

🗨️ What are the key debates in thoracic cancer? ⭐ Don't miss this interview with @StephenVLiu, who joined us to share insights and highlights from the International Thoracic Cancer Debates. ➡️ Watch: buff.ly/TfsVYN3 #ITCD26 #lcsm #NSCLC #SCLC #LungCancer

Enjoyed discussing our different approaches to the same challenges at the 2026 Summit at the Summit. It's enormously helpful to understand different perspectives and come together to prioritize future directions. Thanks to chairs @PatelOncology @benlevylungdoc @christine_lovly

We are encouraging everyone on diagnosis pan-tumor to be tested for MET overexpression by IHC. We applaud those in academic medicine and in the community who are ordering MET IHC and HER2 IHC.

@NRG1Energizers @LC_Initiative_ @LUNGevity @met_crusaders @TheWRP4LC @metcrusaders Thank you!

The deadline is tomorrow, March 18. Every 4.2 minutes, someone in the United States dies of lung cancer. Lung Cancer Research needs your voice. Right now, there's something concrete you can do about it. Give your voice. Learn about how to ACT NOW for Lung Cancer Research Funding from @GO2forLungCancr go2.org/advocacy/take-… Ask your Representative to sign @RepBrendanBoyle's Dear Colleague Letter and support $60 million for the Lung Cancer Research Program in the FY2027 Defense Appropriations bill. This will restore and fully fund this critical peer-reviewed, stand-alone program that drives vital research on lung cancer treatment, prevention, and veteran health. This research saves lives. #LungCancer #LungCancerResearch #LCRP #CancerResearch #HealthPolicy #Advocacy @TeamCalvert @BettyMcCollum04 @HouseDemocrats @HouseGOP @LUNGevity @ABOHLung @metcrusaders @EGFRResisters @LungPolicy @lcfamerica

Targeted therapy reshapes metastatic NSCLC — BRAF V600E, MET exon 14, and KRAS G12C alterations guide precision care. Riely highlights efficacy, toxicity, and real-world decision-making. Dive deeper → hubs.li/Q03VZR4L0 #NSCLC #TargetedTherapy #PrecisionOncology

Targeted RNA Sequencing of Head & Neck Adenoid Cystic Carcinoma Reveals SEC16A::NOTCH1 Fusion & MET Exon 14 Skipping as Potentially Actionable Alterations Chu, Xu, Sukhadia, et al. rdcu.be/eMqDU #HeadNeckPathol #HNPJ #HeadandNeckPath #Pathology #ENTPath #PathologyTweet